Enliven Therapeutics (ELVN) Cash from Investing Activities (2019 - 2026)

Enliven Therapeutics has disclosed Cash from Investing Activities across 8 years of filings, most recently posting $42.5 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $42.5 million, up 2880.1% year-over-year; the trailing twelve-month figure through Mar 2026 was -$132.7 million (down 695.58% YoY), and the FY2025 annual result was -$173.8 million, down 382.93% from the prior year.
• Cash from Investing Activities came in at $42.5 million for Q1 2026 at Enliven Therapeutics, up from $12.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $42.5 million in Q1 2026 to a low of -$183.6 million in Q2 2025.
• The 5-year median for Cash from Investing Activities is -$101000.0 (2022), against an average of -$18.6 million.
• Peak annual rise in Cash from Investing Activities reached 38402.97% in 2023, while the deepest fall reached 253821.43% in 2023.
• Enliven Therapeutics' Cash from Investing Activities stood at -$101000.0 in 2022, then jumped by 38402.97% to $38.7 million in 2023, then plunged by 98.12% to $727000.0 in 2024, then surged by 1602.75% to $12.4 million in 2025, then surged by 243.53% to $42.5 million in 2026.
• The last three Cash from Investing Activities figures came in at $42.5 million (Q1 2026), $12.4 million (Q4 2025), and -$4.1 million (Q3 2025), per Business Quant data.